AstraZeneca pulls lung cancer drug application in EU
Portfolio Pulse from
AstraZeneca has withdrawn its marketing application for the lung cancer drug datopotamab deruxtecan in the EU following feedback from the European Medicines Agency.
December 24, 2024 | 9:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca has voluntarily withdrawn its EU marketing application for the lung cancer drug datopotamab deruxtecan after receiving feedback from the European Medicines Agency.
The withdrawal of a key drug application in the EU could negatively impact AstraZeneca's stock in the short term due to potential delays in market entry and revenue generation. The decision was made after feedback from the EMA, indicating possible regulatory challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100